Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Beyond EGFR inhibitors in advanced colorectal cancer: Targeting BRAF and HER2.

Current problems in cancer - 1 Aug 2023

Dao Vinh, Heestand Gregory

Abstract excerpt

The addition of antiepidermal growth factor receptor (EGFR) monoclonal antibodies, cetuximab or panitumumab, to conventional chemotherapy has improved clinical outcomes for rat sarcoma virus (RAS) wild-type advanced colorectal cancer patients, however, durable responses and 5-year overall survival rates remain limited. BRAF V600E somatic mutation and human epidermal growth factor receptor (HER2)...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Antineoplastic Agents
Share to Colorectal Neoplasms
Share to Mice

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Mutation

Share to Panitumumab

Share to Proto-Oncogene Proteins B-raf

Source

Identifiers

PMID: 37285606
DOI: 10.1016/j.currproblcancer.2023.100960

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Beyond EGFR inhibitors in advanced colorectal cancer: Targeting BRAF and HER2.PMID 37285606Read ↗

Evidence-Based Second-Line Treatment in RAS Wild-Type/Mutated Metastatic Colorectal Cancer in the Precision Medicine Era.Semantic proximity Read ↗

BRAF-Mutated Advanced Colorectal Cancer: A Rapidly Changing Therapeutic Landscape.Semantic proximity Read ↗

Recent Advances in Targeting the EGFR Signaling Pathway for the Treatment of Metastatic Colorectal Cancer.Semantic proximity Read ↗

EGFR Signaling in Colorectal Cancer: Novel Therapeutic Strategies, Predictive Biomarkers, and Counteracting Treatment Resistance.Semantic proximity Read ↗

BRAF Mutation in Colorectal Cancers: From Prognostic Marker to Targetable MutationSemantic proximity Read ↗

BRAF mutant colorectal cancer: prognosis, treatment, and new perspectives.Semantic proximity Read ↗

Targeting BRAF and RAS in Colorectal CancerSemantic proximity Read ↗

Treatment of extended RAS/BRAF wild-type metastatic colorectal cancer with anti-EGFR antibody combinations.Semantic proximity Read ↗

Targeting BRAF V600E in metastatic colorectal cancer: where are we today?Semantic proximity Read ↗

Optimizing treatment of metastatic colorectal cancer patients with anti-EGFR antibodies: overcoming the mechanisms of cancer cell resistance.Semantic proximity Read ↗

Treatment of Advanced BRAF-Mutated Colorectal Cancer: Where We Are and Where We Are Going.Semantic proximity Read ↗

BRAF Mutations in Colorectal Cancer: Clinical Relevance and Role in Targeted TherapySemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.